Company profile
Relay Therapeutics, Inc.
NASDAQ: RLAY · Healthcare · Biotechnology
#581 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
58CFH 53DQ 62GM 60SS 64
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ growth stability, operating margin
Methodology →Revenue TTM
$10.3M
Rev growth YoY (TTM)
+23.9%
Net income (FY)
-$276.5M
Employees
192
as of 2026-08-08
Market cap
$3.5B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.4M$15.4M2025
Net income-$276.5M-$276.5M2025
Operating income-$302.7M-$302.7M2025
Total assets$621.3M$621.3M2025
Liabilities$54.3M$54.3M2025
Equity$567.1M$567.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Relay Therapeutics, Inc.’s revenue?
Relay Therapeutics, Inc. booked $15.4M in FY2025 revenue, growing 53% year over year — faster than most Healthcare companies we track, at a -1800.6% net margin.
Peers · Healthcare
Patient Portal Technologies, Inc.——Green Growth Brands Inc.——Neuphoria Therapeutics Inc.44DAllurion Technologies Inc.26DVSee Health, Inc.35DLineage Cell Therapeutics, Inc.56CNeighbors
Middlesex →Key facts
CEOSanjiv K. Patel
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: RLAY
Employees192
IPO date2020-07-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.